Table 2.
Previously treated anti-retroviral therapy.
| Latest Regimen | Latest ART | Number |
|---|---|---|
| 2NRTIs + PIs | ABC/3TC/ATV/COBI | 2 |
| 3TC/ABC + ATV | 1 | |
| 3TC/ABC + LPV/r | 1 | |
| 2NRTIs + INSTIs | DTG/ABC/3TC | 101 |
| BIC/FTC/TAF | 8 | |
| ABC/3TC + RAL | 5 | |
| TDF/FTC + RAL | 3 | |
| TAF/FTC + RAL | 1 | |
| TAF/FTC + DTG | 1 | |
| 2NRTIs + NNRTIs | ETR + ABC + 3TC | 1 |
| ZDV/3TC + EFV | 2 | |
| 3TC/ABC + EFV | 2 | |
| TAF/FTC + EFV | 1 | |
| NRTIs + PIs + INSTIs | EVG/COBI/FTC/TAF | 2 |
Data are presented as number of patients. NRTIs; Nucleoside and nucleotide reverse transcriptase inhibitors, NNRTIs; Non-nucoleoside reverse transcriptase inhibitors, PIs; Protease inhibitors, INSTIs; Integrase strand trasnfer inhibitors, ABC; Abacavir, 3TC; Lamivudine, ATV; Atazanavir, COBI; Cobicistat, DRV; Darunavir, BIC; Bictegravir, FTC; Emtricitabine, TAF; Tenofovir alafenamide, TDF; Tenofovir disoproxil fumarate, RAL; Raltegravir, ETR; Etravirine, ZDV; Zodivudine, EFV; Efavirenz, EVG; Elvitegravir.